BridgeBio Pharma Inc
NASDAQ:BBIO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
30.14
79.91
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
BridgeBio Pharma Inc
BridgeBio Pharma Inc. stands as a compelling figure in the biotechnology sector, driven by its mission to address and rectify genetic diseases at their root. Formed with the belief that breakthrough medicines for genetic disorders could be developed with unprecedented speed and precision, the company focuses on identifying clinically validated genetic pathways. By collaborating with leading researchers and utilizing sophisticated drug development platforms, BridgeBio seeks to rapidly translate genetic insights into medical innovations. The company's distinct approach concentrates on single-gene disorders across various therapeutic areas including oncology, cardiology, dermatology, and neurology.
The financial workings of BridgeBio Pharma revolve around its robust pipeline of targeted therapies. Essentially, its revenue model is anchored in developing investigational therapies that hold the potential for lucrative partnerships and licensing deals with larger pharmaceutical entities. As these therapies progress through clinical stages, their valuation—and hence the potential for revenue—significantly increases. BridgeBio also leverages a strategy of creating subsidiary companies for each drug in its pipeline, promoting both focus and accountability. This organizational structure enables efficient capital allocation and innovation while also opening up opportunities for public market offerings and strategic exits, thereby driving the financial engine of BridgeBio.
BridgeBio Pharma Inc. stands as a compelling figure in the biotechnology sector, driven by its mission to address and rectify genetic diseases at their root. Formed with the belief that breakthrough medicines for genetic disorders could be developed with unprecedented speed and precision, the company focuses on identifying clinically validated genetic pathways. By collaborating with leading researchers and utilizing sophisticated drug development platforms, BridgeBio seeks to rapidly translate genetic insights into medical innovations. The company's distinct approach concentrates on single-gene disorders across various therapeutic areas including oncology, cardiology, dermatology, and neurology.
The financial workings of BridgeBio Pharma revolve around its robust pipeline of targeted therapies. Essentially, its revenue model is anchored in developing investigational therapies that hold the potential for lucrative partnerships and licensing deals with larger pharmaceutical entities. As these therapies progress through clinical stages, their valuation—and hence the potential for revenue—significantly increases. BridgeBio also leverages a strategy of creating subsidiary companies for each drug in its pipeline, promoting both focus and accountability. This organizational structure enables efficient capital allocation and innovation while also opening up opportunities for public market offerings and strategic exits, thereby driving the financial engine of BridgeBio.
Strong Revenue Growth: BridgeBio reported total revenue of $120.7 million in Q3 2025, driven by $108.1 million in net product sales from Attruby, reflecting strong commercial execution.
Pipeline Success: The company announced positive Phase III top-line results for both BBP-418 in limb-girdle muscular dystrophy type 2I and encaleret in autosomal dominant hypocalcemia type 1, meeting all primary and secondary endpoints.
Market Share Momentum: Attruby's share of new patient starts is now estimated to be in the 20% range, with double-digit growth in prescriptions, supporting the goal of 30%+ long-term market share.
Continued Diagnosis Growth: The ATTR-cardiomyopathy market is expanding, with increasing diagnosis and prescription rates, and no signs of market slowdown.
Strong Cash Position: BridgeBio ended Q3 with $645.9 million in cash and equivalents, providing ample runway for future growth and launches.
Upcoming Catalysts: The next key readout will be for infigratinib in achondroplasia in early 2026, adding further diversification opportunities.
Global Expansion: International markets are ramping up, with Bayer achieving nearly 50% new patient share in Germany for BEYONTTRA within six months of launch.
